JAMA Ophthalmol:COVID-19诊断后视网膜血管闭塞发生率的变化

2022-04-24 从医路漫漫 MedSci原创

光学相干断层血管造影术研究发现,与对照组相比,COVID-19感染患者的视网膜血管密度减少。

背景:新冠肺炎感染后可出现多器官病理,包括累及静脉和动脉系统的血管损伤。光学相干断层血管造影术研究发现,与对照组相比,COVID-19感染患者的视网膜血管密度减少。考虑到新冠肺炎感染引起的血栓前状态和观察到的视网膜血管变化,似乎很直观地将这种感染与视网膜血管阻塞联系起来;然而,关于可能联系的数据有限。

目的:探讨新冠肺炎感染后视网膜血管阻塞发生率的变化。

设计、设置和参与者:这项在一个综合性医疗保健组织(南加州凯撒永久医疗机构)进行的队列研究包括在2020年1月20日至2021年5月31日期间被诊断为新冠肺炎感染的无视网膜血管阻塞病史的患者。如果患者在被诊断为新冠肺炎之前有视网膜动脉阻塞(RAOS)或视网膜静脉阻塞(RVO)病史超过6个月,或者如果他们在新冠肺炎诊断之前在南加州凯撒永久医院注册不到6个月,他们就被排除在外。

暴露:新冠肺炎感染。

主要结果和措施:新冠肺炎诊断后新的RAO和RVO平均双周发病率的变化。在考虑了基线人口学特征、病史和住院情况后,计算调整后的发生率比(IRR)以比较新冠肺炎诊断前后视网膜血管阻塞的发生率。

结果:本研究共纳入432515例新冠肺炎感染者。平均年龄40.9岁(19.2岁),女性231767例(53.6%)。在新冠肺炎诊断后的6个月内,16例患者有RAO(粗发病率,3.00/100万患者),65例患者有RVO(粗发病率,12.20/100万患者)。在调整了年龄、性别、自我报告的种族和民族、体重指数、糖尿病、高血压或高脂血症病史和住院等因素后,新冠肺炎感染后6个月的新RVO发生率高于感染前6个月(调整后的IRR1.54;95%CI,1.05-2.26;P=.03)。新冠肺炎诊断后RAOS的发生率增加较小(IRR1.35;95%CI为0.64~2.85;P=0.44)。RAOS和RVOS的发病高峰分别出现在新冠肺炎确诊后10~12周和6~8周。

表1 相对于新冠肺炎诊断日期的RAO和RVO的平均发生率

表2 根据视网膜血管阻塞状况分层的新冠肺炎感染患者的基线特征

表3 新冠肺炎诊断后住院的视网膜血管阻塞的未校正和校正IRRs

结论:这项研究的结果表明,新冠肺炎感染后RVO的发生率有所增加;然而,这些事件仍然很少见,在没有随机对照的情况下,无法建立因果关系。有必要进行更大规模的流行病学研究,以更好地确定视网膜血栓栓塞症事件和新冠肺炎感染之间的联系。

原文出处:Modjtahedi BS,  Do D,  Luong TQ,  Shaw J,Changes in the Incidence of Retinal Vascular Occlusions After COVID-19 Diagnosis.AMA Ophthalmol 2022 Apr 14

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2009890, encodeId=057f200989098, content=<a href='/topic/show?id=467789803a9' target=_blank style='color:#2F92EE;'>#血管闭塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89803, encryptionId=467789803a9, topicName=血管闭塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=827b160, createdName=cnxcy, createdTime=Wed Dec 07 13:30:42 CST 2022, time=2022-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826798, encodeId=df801826e98c9, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat Apr 23 23:30:42 CST 2022, time=2022-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270301, encodeId=644412e03019f, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Tue Apr 19 07:30:42 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541472, encodeId=875115414e2ce, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Tue Apr 19 07:30:42 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1243467, encodeId=2e6f124346eb4, content=JAMA上文章都是顶级的,谢谢梅斯及时上新, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Sun Apr 17 19:30:42 CST 2022, time=2022-04-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2009890, encodeId=057f200989098, content=<a href='/topic/show?id=467789803a9' target=_blank style='color:#2F92EE;'>#血管闭塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89803, encryptionId=467789803a9, topicName=血管闭塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=827b160, createdName=cnxcy, createdTime=Wed Dec 07 13:30:42 CST 2022, time=2022-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826798, encodeId=df801826e98c9, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat Apr 23 23:30:42 CST 2022, time=2022-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270301, encodeId=644412e03019f, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Tue Apr 19 07:30:42 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541472, encodeId=875115414e2ce, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Tue Apr 19 07:30:42 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1243467, encodeId=2e6f124346eb4, content=JAMA上文章都是顶级的,谢谢梅斯及时上新, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Sun Apr 17 19:30:42 CST 2022, time=2022-04-17, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2009890, encodeId=057f200989098, content=<a href='/topic/show?id=467789803a9' target=_blank style='color:#2F92EE;'>#血管闭塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89803, encryptionId=467789803a9, topicName=血管闭塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=827b160, createdName=cnxcy, createdTime=Wed Dec 07 13:30:42 CST 2022, time=2022-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826798, encodeId=df801826e98c9, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat Apr 23 23:30:42 CST 2022, time=2022-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270301, encodeId=644412e03019f, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Tue Apr 19 07:30:42 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541472, encodeId=875115414e2ce, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Tue Apr 19 07:30:42 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1243467, encodeId=2e6f124346eb4, content=JAMA上文章都是顶级的,谢谢梅斯及时上新, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Sun Apr 17 19:30:42 CST 2022, time=2022-04-17, status=1, ipAttribution=)]
    2022-04-19 zutt
  4. [GetPortalCommentsPageByObjectIdResponse(id=2009890, encodeId=057f200989098, content=<a href='/topic/show?id=467789803a9' target=_blank style='color:#2F92EE;'>#血管闭塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89803, encryptionId=467789803a9, topicName=血管闭塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=827b160, createdName=cnxcy, createdTime=Wed Dec 07 13:30:42 CST 2022, time=2022-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826798, encodeId=df801826e98c9, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat Apr 23 23:30:42 CST 2022, time=2022-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270301, encodeId=644412e03019f, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Tue Apr 19 07:30:42 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541472, encodeId=875115414e2ce, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Tue Apr 19 07:30:42 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1243467, encodeId=2e6f124346eb4, content=JAMA上文章都是顶级的,谢谢梅斯及时上新, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Sun Apr 17 19:30:42 CST 2022, time=2022-04-17, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2009890, encodeId=057f200989098, content=<a href='/topic/show?id=467789803a9' target=_blank style='color:#2F92EE;'>#血管闭塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89803, encryptionId=467789803a9, topicName=血管闭塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=827b160, createdName=cnxcy, createdTime=Wed Dec 07 13:30:42 CST 2022, time=2022-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826798, encodeId=df801826e98c9, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat Apr 23 23:30:42 CST 2022, time=2022-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270301, encodeId=644412e03019f, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Tue Apr 19 07:30:42 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541472, encodeId=875115414e2ce, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Tue Apr 19 07:30:42 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1243467, encodeId=2e6f124346eb4, content=JAMA上文章都是顶级的,谢谢梅斯及时上新, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Sun Apr 17 19:30:42 CST 2022, time=2022-04-17, status=1, ipAttribution=)]
    2022-04-17 肿瘤克星

    JAMA上文章都是顶级的,谢谢梅斯及时上新

    0

相关资讯

JAMA Neurology:COVID-19 患者嗅觉组织存在轴突损伤和微血管病变

COVID-19 感染与嗅觉组织中的轴突损伤和微血管病变有关。

CMI:COVID-19和疟疾合并感染对临床结局的影响

在疟疾流行地区抗击新冠肺炎病毒受到了生态学研究的影响,这些研究表明,疟疾发病率较高的国家往往具有较低的新冠肺炎死亡率

细胞骨架破坏剂sabizabulin将COVID-19死亡人数减少了55%

Veru 表示,由于“压倒性”的有效性,该研究在独立数据监测委员会的建议下提前停止。

Radiolog:COVID-19突破性感染的影像学和临床特征

突破性感染被定义为在接受所有推荐剂量的COVID-19疫苗后≥14天,从一个人的呼吸道标本中检测到严重急性呼吸系统综合症冠状病毒2(SARS-CoV-2)的核糖核酸(RNA)或抗原。

ACC 2022:新冠疫情全国“多点开花”,COVID-19并发急性心梗患者不容忽视!

感染严重急性呼吸综合征冠状病毒2(SARS-CoV-2)并发生临床疾病2019冠状病毒病(COVID-19)的患者通常症状轻微或无症状。较严重的表现包括肺炎和急性呼吸窘迫综合征。

BMJ:Covid-19后深静脉血栓形成、肺栓塞和出血的风险

新冠肺炎是深静脉血栓形成、肺栓塞和出血的危险因素。这些结果可能会影响covid-19后静脉血栓栓塞的诊断和预防策略。